News

The transaction, latest in a series of biotech deals by major drug firms facing the prospect of patent cliff for their blockbuster drugs, will exceed $500m if several

ella was approved by the US Food and Drug Administration (FDA) as safe and effective in helping to prevent unintended pregnancy for up to five days after unprotected

The grant has been made to defer some of the company’s research expenditures related to the development of its novel and patented technology, CollaFix, as a drug delivery

The BioClinica Certified Partner (BCP) Program helps CROs address many of the complexities associated with clinical trials by leveraging the focus and the power of BioClinica software and

APHP, an association of all 44 public hospitals in Paris, is a public health network in France. It is providing medical service for the complete metropolitan area of

The Phase 2b trial is a multicenter, randomized, double-blind, placebo-controlled study in HIV infected patients receiving antiretroviral therapy (ART) to evaluate the efficacy and safety of AGS-004 when

Caleco Pharma is a healthcare company with biopharmaceutical and consumer health product development programs that develop products derived from natural sources such as plant extracts. In response to

Lucassin is being developed for the treatment of hepatorenal syndrome (HRS) Type 1. Lucassin is a synthetic vasopressin analogue that acts via the vasopressin V1a receptor as a

Array anticipates initiating a Phase 1 dose escalation trial in cancer patients with ARRY-382, a small molecule cFMS inhibitor, during the first quarter of 2011. Under the agreement,